Laboratorios Casen Fleet S.L.U

Autovia De Logrono KM 13, 3 Utebo-Zaragoza, 50180, Spain
Telephone: +34976462626
Telephone: 07792 983959 (UK Sales enquiries)
Telephone: 08082343863 - FREE TOLL NUMBER UK.
Fax: +34976771560
E-mail: pwilliams@casenfleet.com (UK Sales enquiries)
E-mail: barajasc@cbfleet.com (PV matters)
E-mail: centrodeinformacion@casenfleet.com
WWW: http://www.casenfleet.com
Medical Information Direct Line: +34913517964
Customer Care direct line: +34913518800
Medical Information Fax: +34913518799


Summary of Product Characteristics last updated on the eMC: 07/04/2008
SPC Fleet Ready-to-Use Enema


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Fleet Ready-to-Use 21.4g / 9.4g Enema


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

 

Per 118ml delivered dose

Sodium Dihydrogen Phosphate Dihydrate

18.1% w/v

Disodium Phosphate Dodecahydrate

8.0% w/v

The delivered dose contains 4.4 g of sodium

For a full list of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Rectal Solution (Enema)

Clear, colourless, odourless, solution, free from precipitation and turbidity.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

• For use in the relief of occasional constipation

• For use where bowel cleansing is required, such as before and after lower bowel surgery, delivery and post partum, before proctoscopy, sigmoidoscopy or colonoscopy and before radiological examinations of the lower bowel


Go to top of the page
4.2 Posology and method of administration

Posology

Adults, Elderly and Children over 12 years old: 1 bottle (118ml delivered dose) no more than once daily or as directed by a physician

Children aged 3 years to less than 12 years: As directed by a physician.

Do not administer to children under 3 years of age

Method of administration

For rectal use only:

Lie on left side with both knees bent, arms at rest.

Remove orange protective shield.

With steady pressure, gently insert enema Comfortip into anus with nozzle pointing towards navel.

Squeeze bottle until nearly all liquid is expelled.

Discontinue use if resistance is encountered. Forcing the enema can result in injury.

Return enema to carton for disposal.

Generally, 2 to 5 minutes are sufficient to obtain the desired effect. If delayed discontinue further use and consult a physician

For occasional constipation rectal enemas are to be used to provide short-term relief only.


Go to top of the page
4.3 Contraindications

Fleet Ready-to-Use Enema is contraindicated in patients with:

• hypersensitivity to active ingredients or to any of the excipients of the product.

• Conditions causing decreased gastric motility, e.g.,

o suspected intestinal obstruction

o paralytic ileus

o anorectal stenosis

o imperforate anus

o congenital or acquired megacolon

o Hirschsprung's Disease

• Undiagnosed gastrointestinal pathology, e.g.,

o symptoms of appendicitis, intestinal perforation or active inflammatory bowel disease

o undiagnosed rectal bleeding

• congestive heart failure

• dehydration and generally in all cases where absorption capacity is increased or elimination capacity is decreased

• Children under 3 years of age


Go to top of the page
4.4 Special warnings and precautions for use

Do not use Fleet Ready-to-use enema when nausea, vomiting or abdominal pain is present unless directed by a physician.

Patients should be advised to expect liquid stools and should be encouraged to drink clear liquids to help prevent dehydration

Use with caution in: elderly or debilitated patients and in patients with uncontrolled arterial hypertension, ascites, heart disease, rectal mucosal changes (ulcers, fissures), colostomy or pre-existing electrolyte imbalance as hypocalcaemia, hypokalaemia, hyperphosphataemia, hypernatraemia and acidosis may occur. Where electrolyte disorders are suspected and in patients who may experience hyperphosphataemia, electrolyte levels should be monitored before and after administration of Fleet Ready-to-Use Enema.

The product should be used with caution in patients with abnormal renal function. Where the clinical benefit is expected to outweigh the risk of hyperphosphataemia

Repeated and prolonged use of Fleet Ready-to-Use Enema is not recommended as it may cause habituation. Unless directed by a physician, Fleet Ready-to-use enema should not be used for more than two weeks.

Rectal bleeding or failure in bowel evacuation after using Fleet Ready-to-Use Enema (evacuation occurs within 5 minutes of administration) may indicate a serious condition. No further administrations should be given and the condition of the patient should be assessed by a physician.

Fleet Ready-to-Use Enema should be administered following the instructions for use and handling (see section 4.2). Patients should be warned to stop administration if resistance is felt because forced administration may cause local damage.

Keep all medicines out of the reach and sight of children.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Use with caution in patients taking calcium channel blockers, diuretics, lithium treatment or other medications that might affect electrolyte levels as hyperphosphataemia, hypocalcaemia, hypokalaemia, hypernatraemic dehydration and acidosis may occur.

As hypernatraemia is associated with lower lithium levels, concomitant use of Fleet RTU Enema and lithium therapy could lead to a fall in serum lithium levels with a lessening of effectiveness.


Go to top of the page
4.6 Pregnancy and lactation

As there is no relevant data available to evaluate the potential for foetal malformation or other foetotoxic effects when administered during pregnancy Fleet Ready-to-Use Enema should only be used as directed by a physician at the time of delivery or postpartum.

As sodium phosphate may pass into the breast milk, it is advised that breast milk is expressed and discarded for up to 24 hours after receiving the Fleet Ready-to-Use Enema.


Go to top of the page
4.7 Effects on ability to drive and use machines

Not relevant.


Go to top of the page
4.8 Undesirable effects

The frequencies of adverse reactions to Fleet Ready-to-Use Enema are not known (cannot be estimated from the available data). Adverse reactions that have been reported are presented below by System Organ Class and Preferred term.

IMMUNE SYSTEM DISORDERS

Hypersensitivity

e.g. urticria, pruritus

METABOLISM AND NUTRITION DISORDERS

Dehydration

Hyperphosphataemia

Hypocalcaemia

Hypokalaemia

Hypernatraemia

Metabolic acidosis

 

GASTROINTESTINAL DISORDERS

Nausea

Vomiting

Abdominal pain

Abdominal distension

Diarrhoea

Gastrointestinal pain

Pruritis ani

 

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS

Chills

Rectal irritation

Blistering

Stinging

Pruritus

Pain

 


Go to top of the page
4.9 Overdose

There have been fatalities when Fleet Ready-to-use Enema has been administered in excessive doses or retained, used in children or used in obstructed patients.

Hyperphosphataemia, hypocalcaemia, hypernatraemia, hypernatraemic dehydration, acidosis and tetany may occur in overdose or retention.

Recovery from the toxic effects can normally be achieved by rehydration. In severe cases correction of electrolyte changes by providing calcium and magnesium salts (10% calcium gluconate) while promoting elimination of exogenous phosphorus and the use of dialysis should be considered


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

ATC classification: A06AG01 Sodium phosphate enema

Fleet Ready-to-Use Enema will act as a saline laxative when administered by the rectal route. Fluid accumulation in the lower bowel produces distension and promotes peristalsis and bowel movement with only the rectum, sigmoid and part or all of the descending colon being evacuated.


Go to top of the page
5.2 Pharmacokinetic properties

Colonic absorption is probably minimal, but it has been reported that asymptomatic hyperphosphataemia up to 2–3 times above normal phosphorus levels occurs in nearly 25% of individuals with normal renal function after administration of ORAL sodium phosphate containing colonic preparations. Data for rectal solutions has been generated by a small, open-label, healthy volunteer company sponsored study which looked at both 250mL (high volume) and 133mL sodium phosphate enemas. This study confirmed a transient increase in serum phosphate above the upper limit of normal in 30% of subjects, with mean phosphorus levels falling after the 10-minute sample Under normal conditions the greatest phosphorus absorption occurs in the small bowel which is never reached from rectal administration.


Go to top of the page
5.3 Preclinical safety data

No preclinical safety studies have been performed.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Disodium Edetate

Benzalkonium Chloride

Purified water

Nozzle lubricant : white soft paraffin


Go to top of the page
6.2 Incompatibilities

None reported or expected


Go to top of the page
6.3 Shelf life

3 years


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C.

Do not refrigerate


Go to top of the page
6.5 Nature and contents of container

Fleet Ready-to-Use Enema is supplied in a 133ml disposable LDPE squeeze bottle, fitted with a LDPE cap, neoprene/isoprene free-latex valve and a soft pre-lubricated Comfortip (ethylene vinyl acetate), which is covered by a protective LDPE shield until use.

The bottle contains 133ml of Fleet Ready-to-Use Enema, which gives a delivered dose of 118ml.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Laboratorios Casen-Fleet S.L.U.

Autovía de Logroño, Km 13,300

50180 UTEBO

Zaragoza

Spain


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 12695/0003


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

07th October 1993 / 09th February 1999 / 09th February 2004


Go to top of the page
10. DATE OF REVISION OF THE TEXT

October 2007



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/542/SPC/